查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲臨床生物標記市場 - 分析與預測（2023-2033）
市場調查報告書
商品編碼
1514760

歐洲臨床生物標記市場 - 分析與預測（2023-2033）

Europe Clinical Biomarkers Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 70 Pages | 商品交期: 1-5個工作天內

價格

2023年歐洲臨床生物標記市場規模達71.9億美元。

預計2023年至2033年該市場將以7.52%的複合年成長率成長，2033年達到148.4億美元。臨床生物標記是可測量的生物因素，有助於早期診斷和了解疾病的進展。這些分子生物標記為疾病研究和治療藥物開發提供了新途徑。

主要市場統計數據
預測期 2023-2033
2023年評估 71.9億美元
2033 年預測 148.4億美元
複合年成長率 7.52%

在生物技術和分子生物學發展的推動下，歐洲臨床生物標記市場正在顯著擴張。臨床生物標記是可測量的生物因素。它對於了解疾病的病程、幫助早期診斷和發現新的治療標靶至關重要。預後、預測和診斷生物標記只是該領域眾多基於生物標記的測試和相關服務的一小部分。推動該產業發展的三個關鍵促進因素是：研發投資的增加、個人化治療需求的增加以及慢性病盛行率的上升。此外，歐洲法規環境正在發生變化，以促進新型生物標記技術的創建和應用。為了滿足不斷成長的需求，頂級製造商和服務供應商正致力於擴大其產品陣容並提高技術力。

本報告考察了歐洲臨床生物標記市場，概述了市場、國家趨勢以及進入市場的公司概況。

目錄

執行摘要

第1章 市場

第2章 市場範圍

第3章調查方法

第4章市場概況

  • 介紹
  • 精準醫學中的臨床生物標記方法
  • 2022-2033 年潛在臨床生物標記市場規模
  • COVID-19 對臨床生物標記市場的影響
  • 市場趨勢

第5章 區域

  • 概述
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他

第6章市場-公司簡介

  • 概述
  • ALCEN
  • bioMerieux SA
  • CENTOGENE NV
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • QIAGEN NV
Product Code: BHP2177SS

Introduction to Europe Clinical Biomarkers Market

The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$7.19 Billion
2033 Forecast$14.84 Billion
CAGR7.52%

Market Introduction

The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.

Market Segmentation

Segmentation 1: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

  • ALCEN
  • bioMerieux S.A.
  • CENTOGENE N.V.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.

Table of Contents

Executive Summary

1 Market

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion

2 Market Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Data Sources
    • 3.1.1 Primary Data Source
    • 3.1.2 Secondary Data Sources
      • 3.1.2.1 Open Sources
  • 3.2 Market Estimation Model
  • 3.3 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Clinical Biomarkers Approaches in Precision Medicine
  • 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
  • 4.4 COVID-19 Impact on Clinical Biomarkers Market
    • 4.4.1 COVID-19 Impact on Market Size
  • 4.5 Market Trends
    • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
    • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
    • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
    • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

  • 5.1 Overview
  • 5.2 Europe
    • 5.2.1 Germany
    • 5.2.2 France
    • 5.2.3 U.K.
    • 5.2.4 Italy
    • 5.2.5 Spain
    • 5.2.6 Rest-of-Europe

6 Market - Company Profiles

  • 6.1 Overview
  • 6.2 ALCEN
    • 6.2.1 Company Overview
    • 6.2.2 Role of ALCEN in the Clinical Biomarkers Market
    • 6.2.3 Analyst's Perspective
  • 6.3 bioMerieux S.A.
    • 6.3.1 Company Overview
    • 6.3.2 Role of bioMerieux S.A. in the Clinical Biomarkers Market
    • 6.3.3 Corporate Strategies
      • 6.3.3.1 Funding and Expansion
      • 6.3.3.2 Product Launches
    • 6.3.4 Financials
    • 6.3.5 Analyst's Perspective
  • 6.4 CENTOGENE N.V.
    • 6.4.1 Company Overview
    • 6.4.2 Role of CENTOGENE N.V. in the Clinical Biomarkers Market
    • 6.4.3 Business Strategies
      • 6.4.3.1 Funding
    • 6.4.4 Corporate Strategies
      • 6.4.4.1 Synergistic Activities
    • 6.4.5 Financials
    • 6.4.6 Analyst's Perspective
  • 6.5 Eurofins Scientific
    • 6.5.1 Company Overview
    • 6.5.2 Role of Eurofins Scientific in the Clinical Biomarkers Market
    • 6.5.1 Corporate Strategies
      • 6.5.1.1 Product Launches
    • 6.5.2 Financials
    • 6.5.3 Analyst's Perspective
  • 6.6 F. Hoffmann-La Roche Ltd
    • 6.6.1 Company Overview
    • 6.6.2 Role of F. Hoffmann-La Roche Ltd in the Clinical Biomarkers Market
    • 6.6.3 Business Strategies
      • 6.6.3.1 Product Launches
    • 6.6.4 Corporate Strategies
      • 6.6.4.1 Synergistic Activities
    • 6.6.5 Financials
    • 6.6.6 Analyst's Perspective
  • 6.7 QIAGEN N.V.
    • 6.7.1 Company Overview
    • 6.7.2 Role of QIAGEN N.V. in the Clinical Biomarkers Market
    • 6.7.3 Corporate Strategies
      • 6.7.3.1 Product Launches
    • 6.7.4 Business Strategies
      • 6.7.4.1 Synergistic Activities
    • 6.7.5 Financials
    • 6.7.6 Analyst's Perspective

List of Figures

  • Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 2: Europe Clinical Biomarkers Market Research Methodology
  • Figure 3: Primary Research Methodology
  • Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 6: Biomarkers Used in Various Clinical Areas
  • Figure 7: Europe Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
  • Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
  • Figure 10: Use of Clinical Biomarkers in Personalized Medicine
  • Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
  • Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
  • Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
  • Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 15: Europe Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 16: Europe: Market Dynamics
  • Figure 17: Europe Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 18: Germany Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 19: Share of Cancer Cases in Germany, 2020
  • Figure 20: France Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 21: U.K. Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 22: Italy Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 23: Spain Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 24: Rest-of-Europe Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 25: Total Number of Companies Profiled
  • Figure 26: ALCEN: Service Portfolio
  • Figure 27: bioMerieux S.A.: Product Portfolio
  • Figure 28: bioMerieux S.A.: Overall Financials, $Million, 2020-2022
  • Figure 29: bioMerieux S.A.: Revenue (by Segment), $Million, 2020-2022
  • Figure 30: CENTOGENE N.V.: Service Portfolio
  • Figure 31: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
  • Figure 32: Eurofins Scientific: Service Portfolio
  • Figure 33: Eurofins Scientific: Overall Financials, $Million, 2020-2022
  • Figure 34: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 35: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 36: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 37: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
  • Figure 38: QIAGEN N.V.: Product Portfolio
  • Figure 39: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 40: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 41: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 42: QIAGEN N.V.: R&D Expenditure, $Million, 20202022

List of Tables

  • Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
  • Table 2: List of Product/Service Offered and its Technology